2,3-Dimethyl-pyrazolo<1,5-a>pyrimidin | 4879-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 2,3-Dimethyl-pyrazolo<1,5-a>pyrimidin
• 英文别名: 2,3-dimethyl-pyrazolo[1,5-a]pyrimidine；2,3-Dimethylpyrazolo[1,5-a]pyrimidine
• CAS: 4879-21-4
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: YDTWIPVIMWBKEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20130267521A1

  公开（公告）日：2013-10-10

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本发明描述了调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及用于治疗与激酶活性相关的疾病和状况的化合物、药物组合物和方法，包括PI3激酶活性。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2013154878A1

  公开（公告）日：2013-10-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性，包括PI3激酶活性的化合物和制药组合物，以及与激酶活性，包括PI3激酶活性相关的疾病和病症的治疗方法、化合物和制药组合物。
• THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS
  申请人：Chen Zhaogen

  公开号：US20100022560A1

  公开（公告）日：2010-01-28

  The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

  本发明涉及式（I）的化合物、其制药组合物以及将这些化合物作为促肾上腺皮质激素释放因子1（CRF1）受体拮抗剂来治疗精神和神经内分泌紊乱、神经疾病和代谢综合征。
• Benzazepine derivatives as histamine h3 antagonists
  申请人：Bailey Nicholas

  公开号：US20070060566A1

  公开（公告）日：2007-03-15

  The present invention relates to novel benzazepine derivatives of structure (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. These compounds act as histamine H3 antagonists.

  本发明涉及具有药理活性的新型苯并氮杂环衍生物(I)的结构，其制备过程，包含它们的组合物以及它们在神经和精神障碍治疗中的应用。这些化合物作为组胺H3拮抗剂。